Clinical Cancer Research Grants Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holzer, A. K.
Right arrow Articles by Howell, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holzer, A. K.
Right arrow Articles by Howell, S. B.
Clinical Cancer Research Vol. 10, 6744-6749, October 1, 2004
© 2004 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Cisplatin Rapidly Down-regulates Its Own Influx Transporter hCTR1 in Cultured Human Ovarian Carcinoma Cells

Alison K. Holzer1, Kuniyuki Katano1, Leo W. J. Klomp2 and Stephen B. Howell1

1 Department of Medicine and the Rebecca and John Moores Cancer Center, University of California at San Diego, La Jolla, California; and 2 Department of Metabolic and Endocrine Diseases, University Medical Center Utrecht, The Netherlands

Purpose: Cisplatin (DDP)-resistant cells commonly exhibit reduced drug accumulation. Previous studies have shown that the major copper (Cu) influx transporter CTR1 controls the uptake of DDP in yeast and mammalian cells. The goal of this study was to examine the effect of Cu and DDP on the level and subcellular localization of hCTR1 protein in human ovarian carcinoma cells.

Experimental Design: Cultured human ovarian carcinoma A2780 cells were exposed to DDP and Cu, and the effect on hCTR1 was determined using Western blot analysis and confocal digital deconvolution microscopy.

Results: Loss of hCTR1 was triggered by DDP exposure in a concentration and time-dependent manner. Exposure to 0.5 µmol/L DDP for 5 minutes reduced hCTR1 levels and exposure to DDP concentrations ≥2 µmol/L caused almost complete disappearance. The loss of hCTR1 was observed within 1 minute of the start of exposure to 2 µmol/L DDP. Treatment of cells with 100 µmol/L Cu for 5 minutes produced a smaller effect. Pretreatment of cells with 2 µmol/L DDP for 5 minutes resulted in a 50% decrease in 64Cu uptake, demonstrating that the DDP-induced loss of hCTR1 detected by Western blot analysis and imaging was functionally significant.

Conclusions: DDP down-regulated the amount of its major influx transporter in cultured human ovarian carcinoma cells in a concentration- and time-dependent manner. The effect was observed at DDP concentrations within the range found in the plasma of patients being treated with DDP, and it occurred very quickly relative to the half-life of the drug.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
D. J. Stewart, J.-P. Issa, R. Kurzrock, M. I. Nunez, J. Jelinek, D. Hong, Y. Oki, Z. Guo, S. Gupta, and I. I. Wistuba
Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas
Clin. Cancer Res., June 1, 2009; 15(11): 3881 - 3888.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
N. Pabla, R. F. Murphy, K. Liu, and Z. Dong
The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity
Am J Physiol Renal Physiol, March 1, 2009; 296(3): F505 - F511.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. D. Jandial, S. Farshchi-Heydari, C. A. Larson, G. I. Elliott, W. J. Wrasidlo, and S. B. Howell
Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1
Clin. Cancer Res., January 15, 2009; 15(2): 553 - 560.
[Abstract] [Full Text] [PDF]


Home page
Brief Funct Genomic ProteomicHome page
M. Wang, J. You, K. G. Bemis, T. J. Tegeler, and D. P. G. Brown
Label-free mass spectrometry-based protein quantification technologies in proteomic analysis
Brief Funct Genomic Proteomic, September 1, 2008; 7(5): 329 - 339.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Sinani, D. J. Adle, H. Kim, and J. Lee
Distinct Mechanisms for Ctr1-mediated Copper and Cisplatin Transport
J. Biol. Chem., September 14, 2007; 282(37): 26775 - 26785.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. K. Holzer and S. B. Howell
The Internalization and Degradation of Human Copper Transporter 1 following Cisplatin Exposure.
Cancer Res., November 15, 2006; 66(22): 10944 - 10952.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
A. K. Holzer, N. M. Varki, Q. T. Le, M. A. Gibson, P. Naredi, and S. B. Howell
Expression of the Human Copper Influx Transporter 1 in Normal and Malignant Human Tissues
J. Histochem. Cytochem., September 1, 2006; 54(9): 1041 - 1049.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.